Literature DB >> 11796150

A study of the nicotinic agonist SIB-1553A on locomotion and attention as measured by the five-choice serial reaction time task.

A J Grottick1, R Wyler, G A Higgins.   

Abstract

SIB-1553A is a novel ligand with reputed agonist selectivity at nicotinic receptors containing the beta(4) subunit. As such, it represents an interesting pharmacological tool with which to probe the function of nicotine receptor subtypes. In the present studies, we compared SIB-1553A with nicotine in its ability to stimulate locomotion and to enhance attention in rats as assessed using the five-choice serial reaction time task (5-CSRTT). In nicotine-naive rats, SIB-1553A (10-40 mg/kg) induced a comparable increase in locomotion to nicotine (0.4 mg/kg), whereas in nicotine-sensitised rats, an enhanced locomotor response was seen to nicotine (0.4 mg/kg) but not to SIB-1553A (10-80 mg/kg). Similarly, chronic treatment with either SIB-1553A or nicotine did not lead to a cross-sensitised locomotor response. Unlike nicotine, SIB-1553A-induced locomotion was insensitive to antagonism by either mecamylamine (1 mg/kg) or DH beta E (3 mg/kg), suggesting a non-nicotinic mechanism. In young and aged rats, nicotine (0.4 mg/kg) enhanced attention as demonstrated by an increase in response accuracy and speed. SIB-1553A (3-10 mg/kg) did not mimic any of these changes and at the highest dose tended to disrupt performance. These results lend further support to the involvement of a high affinity site, possibly alpha(4)beta(2), in the locomotor and attentional-enhancing properties of nicotine.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11796150     DOI: 10.1016/s0091-3057(01)00639-6

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  8 in total

1.  Behavioral disinhibition requires dopamine receptor activation.

Authors:  Marcel M van Gaalen; Reinhild J Brueggeman; Patricia F C Bronius; Anton N M Schoffelmeer; Louk J M J Vanderschuren
Journal:  Psychopharmacology (Berl)       Date:  2006-04-25       Impact factor: 4.530

Review 2.  Pharmacological enhancement of memory and executive functioning in laboratory animals.

Authors:  Stan B Floresco; James D Jentsch
Journal:  Neuropsychopharmacology       Date:  2010-09-15       Impact factor: 7.853

Review 3.  Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia.

Authors:  Jared W Young; Susan B Powell; Victoria Risbrough; Hugh M Marston; Mark A Geyer
Journal:  Pharmacol Ther       Date:  2009-03-06       Impact factor: 12.310

Review 4.  Cognition as a therapeutic target in late-life depression: potential for nicotinic therapeutics.

Authors:  Lilia Zurkovsky; Warren D Taylor; Paul A Newhouse
Journal:  Biochem Pharmacol       Date:  2013-08-08       Impact factor: 5.858

5.  A randomized, double-blind, placebo-controlled crossover study of α4β 2* nicotinic acetylcholine receptor agonist AZD1446 (TC-6683) in adults with attention-deficit/hyperactivity disorder.

Authors:  Aurelija Jucaite; John Öhd; Alexandra S Potter; Judith Jaeger; Pär Karlsson; Kristin Hannesdottir; Emma Boström; Paul A Newhouse; Björn Paulsson
Journal:  Psychopharmacology (Berl)       Date:  2013-05-03       Impact factor: 4.530

6.  The nicotinic acetylcholine receptor alpha 4 subunit contains a functionally relevant SNP Haplotype.

Authors:  Marlene Eggert; Georg Winterer; Mario Wanischeck; Jean-Charles Hoda; Daniel Bertrand; Ortrud Steinlein
Journal:  BMC Genet       Date:  2015-05-02       Impact factor: 2.797

Review 7.  Nicotinic acetylcholine receptors in attention circuitry: the role of layer VI neurons of prefrontal cortex.

Authors:  Eliane Proulx; Matthew Piva; Michael K Tian; Craig D C Bailey; Evelyn K Lambe
Journal:  Cell Mol Life Sci       Date:  2014-04       Impact factor: 9.261

8.  Chronic nicotine administration improves attention while nicotine withdrawal induces performance deficits in the 5-choice serial reaction time task in rats.

Authors:  Svetlana Semenova; Ian P Stolerman; Athina Markou
Journal:  Pharmacol Biochem Behav       Date:  2007-05-23       Impact factor: 3.533

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.